Ionis Pharmaceuticals (IONS) Financials

$29.57 +0.47 (+1.62%)

As of 04/24/2025 04:00 PM Eastern

Annual Income Statements for Ionis Pharmaceuticals

This table shows Ionis Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-88	-60	0.35	274	278	-444	-29	-270	-366	-454
Consolidated Net Income / (Loss)	-88	-60	-11	215	287	-480	-29	-270	-366	-454
Net Income / (Loss) Continuing Operations	-88	-60	-11	215	287	-480	-29	-270	-366	-453
Total Pre-Tax Income	-88	-57	-17	-76	339	-135	-29	-258	-334	-460
Total Operating Income	-76	-20	31	-61	366	-172	-30	-410	-354	-475
Total Gross Profit	284	373	514	598	1,118	717	800	573	779	694
Total Revenue	284	373	514	600	1,123	729	810	587	788	705
Operating Revenue	284	373	514	600	1,123	729	810	587	788	705
Total Cost of Revenue	0.00	0.00	0.00	1.82	4.38	12	11	14	9.13	11
Operating Cost of Revenue	-	0.00	0.00	1.82	4.38	12	11	14	9.13	11
Total Operating Expenses	359	393	483	659	752	889	830	983	1,132	1,169
Selling, General & Admin Expense	37	49	108	245	287	354	186	150	233	267
Research & Development Expense	322	344	375	415	466	535	643	833	900	902
Total Other Income / (Expense), net	-12	-37	-48	-15	-27	38	1.04	152	20	14
Interest Expense	37	43	45	45	79	9.51	9.35	8.12	81	90
Interest & Investment Income	25	5.47	8.18	30	52	47	20	18	87	104
Other Income / (Expense), net	0.00	0.00	-11	-0.18	-0.69	-0.06	-9.76	142	14	-0.01
Income Tax Expense	0.37	2.93	-5.98	-291	52	345	-0.55	12	32	-6.17
Other Gains / (Losses), net	-	-	-	-	-	-	-	-	-	1.34
Basic Earnings per Share	($0.74)	($0.50)	$0.15	$2.09	$2.00	($3.18)	($0.20)	($1.90)	($2.56)	($3.04)
Weighted Average Basic Shares Outstanding	119.72M	120.93M	124.02M	132.32M	140.00M	139.61M	141.02M	141.85M	143.19M	149.51M
Diluted Earnings per Share	($0.74)	($0.50)	$0.15	$2.07	$1.90	($3.18)	($0.20)	($1.90)	($2.56)	($3.04)
Weighted Average Diluted Shares Outstanding	119.72M	120.93M	126.10M	134.06M	153.16M	139.61M	141.02M	141.85M	143.19M	149.51M
Weighted Average Basic & Diluted Shares Outstanding	119.72M	120.20M	4.30M	131M	138.70M	140.86M	141.69M	142.95M	145.75M	158.96M

This table shows Ionis Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-47	-52	-124	-85	-147	-9.26	-143	-66	-140	-104
Consolidated Net Income / (Loss)	-47	-52	-124	-85	-147	-9.26	-143	-66	-140	-104
Net Income / (Loss) Continuing Operations	-47	-52	-124	-85	-147	-9.26	-143	-66	-140	-103
Total Pre-Tax Income	-47	-44	-113	-77	-141	-2.77	-143	-66	-144	-107
Total Operating Income	-59	-208	-114	-90	-143	-6.12	-150	-66	-149	-111
Total Gross Profit	158	148	129	186	142	321	117	221	133	223
Total Revenue	160	152	131	188	144	325	119	225	134	227
Operating Revenue	160	152	131	188	144	325	119	225	134	227
Total Cost of Revenue	1.52	3.69	1.34	2.54	2.19	3.06	2.15	4.16	1.07	3.83
Operating Cost of Revenue	1.52	3.69	1.34	2.54	2.19	3.06	2.15	4.16	1.07	3.83
Total Operating Expenses	217	356	243	276	285	328	267	287	281	334
Selling, General & Admin Expense	34	48	46	46	70	71	53	65	62	88
Research & Development Expense	183	308	198	230	215	257	214	222	220	245
Total Other Income / (Expense), net	12	164	1.21	13	2.46	3.36	6.79	-0.11	4.56	2.44
Interest Expense	2.14	1.73	17	20	22	22	22	23	23	23
Interest & Investment Income	9.87	16	18	22	22	26	29	22	27	26
Other Income / (Expense), net	4.71	150	0.23	11	2.45	0.24	0.28	0.61	0.14	-1.04
Income Tax Expense	0.28	8.10	11	7.84	6.60	6.50	0.08	0.06	-3.62	-2.69
Basic Earnings per Share	($0.33)	($0.37)	($0.87)	($0.60)	($1.03)	($0.06)	($0.98)	($0.45)	($0.95)	($0.66)
Weighted Average Basic Shares Outstanding	141.95M	141.85M	142.74M	143.10M	143.32M	143.19M	145.54M	145.96M	148.59M	149.51M
Diluted Earnings per Share	($0.33)	($0.37)	($0.87)	($0.60)	($1.03)	($0.06)	($0.98)	($0.45)	($0.95)	($0.66)
Weighted Average Diluted Shares Outstanding	141.95M	141.85M	142.74M	143.10M	143.32M	143.19M	145.54M	145.96M	148.59M	149.51M
Weighted Average Basic & Diluted Shares Outstanding	142.05M	142.95M	143.09M	143.33M	143.47M	145.75M	145.97M	146.21M	157.90M	158.96M

This table details how cash moves in and out of Ionis Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-14	-44	45	149	404	-286	472	-593	123	-157
Net Cash From Operating Activities	21	-112	174	603	346	36	31	-274	-308	-501
Net Cash From Continuing Operating Activities	21	-112	174	603	346	36	31	-274	-308	-501
Net Income / (Loss) Continuing Operations	-88	-60	-11	215	287	-480	-29	-270	-366	-454
Consolidated Net Income / (Loss)	-88	-60	-11	215	287	-480	-29	-270	-366	-454
Depreciation Expense	6.98	7.48	6.71	11	13	13	15	14	10	9.61
Amortization Expense	41	40	45	36	-1.09	19	27	21	-10	-19
Non-Cash Adjustments To Reconcile Net Income	41	78	97	180	215	202	131	-47	136	171
Changes in Operating Assets and Liabilities, net	20	-178	37	161	-168	281	-114	7.57	-77	-209
Net Cash From Investing Activities	-60	57	-358	-930	-41	274	195	-263	-214	-134
Net Cash From Continuing Investing Activities	-60	57	-358	-930	-41	274	195	-263	-214	-134
Purchase of Property, Plant & Equipment	-12	-12	-38	-18	-31	-35	-12	-16	-24	-45
Acquisitions	-	-	-	-	-5.38	-5.93	-5.95	-4.38	-4.21	-5.06
Purchase of Investments	-493	-301	-880	-1,795	-1,957	-1,570	-1,131	-1,486	-1,771	-1,853
Sale of Property, Plant & Equipment	-	-	-	-	-	0.00	0.00	254	0.02	0.00
Sale and/or Maturity of Investments	420	365	557	883	1,952	1,886	1,344	989	1,585	1,769
Net Cash From Financing Activities	25	11	229	476	100	-597	246	-55	644	478
Net Cash From Continuing Financing Activities	25	11	229	476	100	-597	246	-55	644	478
Repayment of Debt	-9.06	-7.07	-3.60	0.00	-23	0.00	-335	-51	-502	-45
Issuance of Debt	8.50	4.00	60	0.00	110	0.00	633	0.00	575	0.00
Issuance of Common Equity	25	13	255	476	176	52	101	6.37	49	523
Other Financing Activities, net	0.40	1.86	-80	0.00	-128	-13	-153	-11	522	0.00
Effect of Exchange Rate Changes	-	-	-	-0.02	0.09	0.62	-	-	0.35	-0.27
Cash Interest Paid	6.80	7.31	8.04	9.59	9.87	6.25	4.78	2.90	6.51	11
Cash Income Taxes Paid	-	-	0.00	0.00	9.04	26	0.04	5.01	48	-5.62

This table details how cash moves in and out of Ionis Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-207	-39	33	116	-73	47	-50	-55	41	-93
Net Cash From Operating Activities	-24	-200	-134	-97	-109	33	-150	-120	-115	-116
Net Cash From Continuing Operating Activities	-24	-200	-134	-97	-109	33	-150	-120	-115	-116
Net Income / (Loss) Continuing Operations	-47	-52	-124	-85	-147	-9.26	-143	-66	-140	-104
Consolidated Net Income / (Loss)	-47	-52	-124	-85	-147	-9.26	-143	-66	-140	-104
Depreciation Expense	3.82	3.03	2.60	2.62	2.52	2.54	2.55	2.47	2.36	2.24
Amortization Expense	3.83	3.66	-0.55	-2.89	-3.15	-3.76	-4.49	-5.10	-4.33	-4.75
Non-Cash Adjustments To Reconcile Net Income	-31	-124	43	18	45	30	40	43	36	52
Changes in Operating Assets and Liabilities, net	46	-31	-55	-29	-5.93	13	-46	-94	-8.46	-61
Net Cash From Investing Activities	-184	212	-326	70	69	-27	76	62	-341	68
Net Cash From Continuing Investing Activities	-184	212	-326	70	69	-27	76	62	-341	68
Purchase of Property, Plant & Equipment	-5.54	-4.14	-10	-12	-2.14	0.82	-4.49	-6.23	-9.06	-25
Acquisitions	-1.52	-0.87	-1.25	-1.06	-1.10	-0.79	-1.24	-14	13	-2.55
Purchase of Investments	-561	-262	-688	-244	-421	-418	-519	-285	-715	-334
Sale and/or Maturity of Investments	384	225	374	327	493	391	601	368	371	430
Net Cash From Financing Activities	1.83	-51	492	144	-32	41	24	2.56	496	-44
Net Cash From Continuing Financing Activities	1.83	-51	492	144	-32	41	24	2.56	496	-44
Repayment of Debt	-0.09	-51	-0.04	-434	-68	-0.04	-0.04	-0.04	-0.05	-45
Issuance of Common Equity	2.57	0.34	2.56	2.39	3.73	41	24	2.60	496	0.43
Cash Interest Paid	0.66	0.69	0.09	0.44	0.42	5.56	0.10	5.47	0.15	5.16
Cash Income Taxes Paid	-	5.01	0.29	0.22	0.20	48	0.01	1.98	0.08	-7.69

This table presents Ionis Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	948	912	1,323	2,668	3,233	2,390	2,612	2,534	2,990	3,004
Total Current Assets	837	798	1,169	2,208	2,721	2,131	2,345	2,203	2,642	2,620
Cash & Equivalents	129	85	130	279	683	398	869	276	399	242
Short-Term Investments	675	581	893	1,805	1,816	1,495	1,246	1,710	1,932	2,056
Inventories, net	6.90	7.49	9.98	8.58	18	22	25	22	7.44	13
Other Current Assets	15	17	136	115	203	216	205	194	303	310
Plant, Property, & Equipment, net	90	93	122	132	154	181	178	74	71	94
Total Noncurrent Assets	21	22	32	328	359	78	89	257	277	289
Other Noncurrent Operating Assets	1.35	1.33	10	13	28	50	89	257	277	289
Total Liabilities & Shareholders' Equity	948	912	1,323	2,668	3,233	2,390	2,612	2,534	2,990	3,004
Total Liabilities	747	813	957	1,481	1,549	1,646	1,840	1,961	2,603	2,415
Total Current Liabilities	149	134	244	280	273	599	241	312	448	309
Short-Term Debt	-	-	-	14	0.00	309	-	0.00	44	0.00
Accounts Payable	28	21	25	29	16	17	12	18	26	43
Accrued Expenses	28	36	67	48	67	90	89	140	148	108
Current Deferred Revenue	67	51	125	160	118	108	98	91	151	79
Current Deferred & Payable Income Tax Liabilities	-	-	-	0.86	33	1.32	0.04	6.25	2.15	0.03
Current Employee Benefit Liabilities	16	24	25	29	37	66	39	49	68	70
Other Current Liabilities	9.03	1.19	1.62	-	2.03	7.30	3.53	7.54	8.83	9.28
Total Noncurrent Liabilities	598	679	714	1,200	1,276	1,048	1,599	1,649	2,155	2,106
Long-Term Debt	389	501	593	628	770	600	1,221	1,183	1,230	1,245
Capital Lease Obligations	-	-	-	-	-	-	19	179	171	162
Noncurrent Deferred Revenue	134	91	108	567	490	424	352	288	241	157
Other Noncurrent Operating Liabilities	75	87	13	4.91	16	23	6.95	0.00	514	542
Total Equity & Noncontrolling Interests	201	100	365	1,187	1,685	743	772	573	387	588
Total Preferred & Common Equity	201	100	281	1,048	1,471	743	772	573	387	588
Total Common Equity	201	100	281	1,048	1,471	743	772	573	387	588
Common Stock	1,309	1,311	1,554	2,047	2,204	1,896	1,964	2,060	2,215	2,869
Retained Earnings	-1,095	-1,181	-1,241	-967	-708	-1,131	-1,160	-1,430	-1,796	-2,250
Accumulated Other Comprehensive Income / (Loss)	-14	-30	-32	-32	-25	-21	-33	-57	-33	-31

This table presents Ionis Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	2,422	2,885	2,971	2,934	2,764	2,691	3,081
Total Current Assets	2,152	2,543	2,617	2,585	2,416	2,329	2,714
Cash & Equivalents	315	309	425	352	349	294	335
Short-Term Investments	1,667	2,038	1,961	1,884	1,857	1,785	2,149
Inventories, net	21	22	26	26	30	29	28
Other Current Assets	150	174	206	323	179	222	202
Plant, Property, & Equipment, net	181	85	92	71	73	76	83
Total Noncurrent Assets	89	257	263	278	275	286	285
Other Noncurrent Operating Assets	59	257	263	278	275	286	285
Total Liabilities & Shareholders' Equity	2,422	2,885	2,971	2,934	2,764	2,691	3,081
Total Liabilities	1,828	2,399	2,543	2,619	2,467	2,427	2,419
Total Current Liabilities	283	259	288	404	328	306	305
Short-Term Debt	-	-	-	-	44	44	44
Accounts Payable	21	10	24	5.62	13	9.24	9.05
Accrued Expenses	128	113	105	119	106	114	124
Current Deferred Revenue	100	92	96	205	130	94	76
Current Deferred & Payable Income Tax Liabilities	0.02	17	25	31	2.21	0.28	0.04
Current Employee Benefit Liabilities	30	18	29	34	22	35	41
Other Current Liabilities	4.97	8.24	8.90	9.95	9.99	8.80	10
Total Noncurrent Liabilities	1,544	2,139	2,255	2,214	2,140	2,121	2,114
Long-Term Debt	1,224	1,177	1,299	1,230	1,189	1,191	1,192
Capital Lease Obligations	-	177	175	173	169	166	168
Noncurrent Deferred Revenue	295	273	254	249	215	189	174
Other Noncurrent Operating Liabilities	25	513	527	562	567	576	580
Total Equity & Noncontrolling Interests	594	487	428	315	297	264	662
Total Preferred & Common Equity	594	487	428	315	297	264	662
Total Common Equity	594	487	428	315	297	264	662
Common Stock	2,035	2,090	2,118	2,148	2,270	2,304	2,832
Retained Earnings	-1,377	-1,554	-1,639	-1,787	-1,939	-2,005	-2,145
Accumulated Other Comprehensive Income / (Loss)	-63	-49	-51	-46	-35	-35	-24

This table displays calculated financial ratios and metrics derived from Ionis Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	32.47%	31.40%	37.93%	16.63%	87.20%	-35.04%	11.13%	-27.53%	34.10%	-10.48%
EBITDA Growth	-89.90%	198.76%	158.62%	-120.91%	2,633.64%	-137.22%	101.67%	-10,023.08%	-45.79%	-42.53%
EBIT Growth	-58.73%	73.39%	198.26%	-410.72%	693.30%	-147.14%	76.80%	-570.56%	-26.80%	-39.88%
NOPAT Growth	-58.73%	73.39%	254.00%	-297.67%	822.18%	-138.83%	82.46%	-1,258.88%	13.76%	-34.31%
Net Income Growth	-126.45%	31.58%	82.15%	2,093.74%	33.62%	-267.01%	94.04%	-843.18%	-35.80%	-23.92%
EPS Growth	-124.24%	32.43%	130.00%	1,280.00%	-8.21%	-267.37%	93.71%	-850.00%	-34.74%	-18.75%
Operating Cash Flow Growth	236.12%	-630.67%	255.34%	246.20%	-42.67%	-89.62%	-14.19%	-990.84%	-12.08%	-62.90%
Free Cash Flow Firm Growth	-136.10%	-877.58%	112.99%	598.20%	-32.12%	-25.47%	-312.46%	-112.73%	159.23%	-365.34%
Invested Capital Growth	-20.50%	69.53%	0.91%	-295.19%	82.34%	-433.22%	57.26%	49.03%	-855.25%	39.57%
Revenue Q/Q Growth	-10.50%	56.73%	-3.51%	4.23%	36.73%	-21.81%	22.66%	-32.91%	28.07%	-12.19%
EBITDA Q/Q Growth	-165.52%	126.94%	-51.17%	53.04%	136.21%	-225.23%	100.97%	-572.07%	11.58%	-28.46%
EBIT Q/Q Growth	-2,663.02%	86.60%	-78.77%	21.56%	215.79%	-255.42%	85.87%	-2,637.52%	13.37%	-28.71%
NOPAT Q/Q Growth	-2,663.02%	86.60%	-77.52%	21.67%	-20.66%	-286.89%	88.96%	-2,495.45%	36.34%	-28.27%
Net Income Q/Q Growth	-721.33%	67.15%	-121.39%	321.83%	-28.55%	-850.78%	95.30%	-3,784.22%	10.54%	-26.50%
EPS Q/Q Growth	-716.67%	67.11%	-67.39%	1,085.71%	-40.44%	-776.60%	95.38%	-3,266.67%	10.80%	-24.59%
Operating Cash Flow Q/Q Growth	-83.66%	8.66%	37.22%	18.73%	88.56%	-83.36%	141.11%	-311.85%	43.11%	-42.34%
Free Cash Flow Firm Q/Q Growth	-132.33%	-135.70%	187.27%	-64.55%	326.45%	197.97%	-367.71%	-101,558.85%	666.96%	-47.33%
Invested Capital Q/Q Growth	-88.71%	56.43%	-125.35%	48.96%	30.23%	-415.54%	41.19%	67.88%	3.25%	27.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	99.70%	99.61%	98.36%	98.66%	97.60%	98.84%	98.41%
EBITDA Margin	-9.81%	7.38%	13.83%	-2.48%	33.55%	-19.23%	0.29%	-39.67%	-43.13%	-68.66%
Operating Margin	-26.70%	-5.41%	6.04%	-10.23%	32.59%	-23.60%	-3.72%	-69.84%	-44.91%	-67.37%
EBIT Margin	-26.70%	-5.41%	3.85%	-10.26%	32.53%	-23.61%	-4.93%	-45.60%	-43.12%	-67.38%
Profit (Net Income) Margin	-31.12%	-16.20%	-2.10%	35.85%	25.59%	-65.78%	-3.53%	-45.92%	-46.50%	-64.37%
Tax Burden Percent	100.42%	105.11%	64.33%	-282.30%	84.80%	356.55%	98.11%	104.55%	109.68%	98.66%
Interest Burden Percent	116.03%	285.05%	-84.62%	123.72%	92.76%	78.16%	72.97%	96.31%	98.33%	96.84%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	15.20%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-38.50%	-40.22%	-4.64%	27.70%	20.01%	-39.52%	-3.78%	-40.12%	-76.34%	-93.10%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-7.96%	-2.17%	1.77%	-3.09%	12.38%	-6.12%	-1.60%	-10.41%	-12.30%	-15.85%
Return on Assets (ROA)	-9.27%	-6.49%	-0.96%	10.77%	9.74%	-17.06%	-1.14%	-10.48%	-13.26%	-15.15%
Return on Common Equity (ROCE)	-38.50%	-40.22%	-3.80%	23.71%	17.55%	-36.05%	-3.78%	-40.12%	-76.34%	-93.10%
Return on Equity Simple (ROE_SIMPLE)	-43.97%	-60.66%	-3.84%	20.51%	19.53%	-64.54%	-3.71%	-47.08%	-94.72%	-77.15%
Net Operating Profit after Tax (NOPAT)	-53	-14	22	-43	310	-120	-21	-287	-248	-333
NOPAT Margin	-18.69%	-3.79%	4.23%	-7.16%	27.64%	-16.52%	-2.61%	-48.88%	-31.44%	-47.16%
Net Nonoperating Expense Percent (NNEP)	-8.29%	-15.98%	-10.94%	27.56%	-1.45%	-26.49%	-0.80%	2.32%	-15.70%	-13.66%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-14.84%	-13.52%	-16.66%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.30%	0.39%	1.64%	1.34%	2.40%	1.16%	1.59%
SG&A Expenses to Revenue	13.10%	13.04%	21.10%	40.79%	25.53%	48.59%	22.99%	25.59%	29.53%	37.93%
R&D to Revenue	113.60%	92.37%	72.86%	69.14%	41.48%	73.37%	79.39%	141.84%	114.22%	127.85%
Operating Expenses to Revenue	126.70%	105.41%	93.96%	109.93%	67.02%	121.96%	102.39%	167.43%	143.75%	165.78%
Earnings before Interest and Taxes (EBIT)	-76	-20	20	-62	365	-172	-40	-268	-340	-475
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-28	27	71	-15	377	-140	2.35	-233	-340	-484
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	37.05	58.22	22.34	7.10	5.78	10.64	5.57	9.37	18.77	9.38
Price to Tangible Book Value (P/TBV)	40.99	73.20	24.24	7.26	5.88	11.05	5.57	9.37	18.77	9.38
Price to Revenue (P/Rev)	26.22	15.55	12.21	12.40	7.57	10.84	5.30	9.13	9.22	7.83
Price to Earnings (P/E)	0.00	0.00	18,142.24	27.17	30.55	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.01%	3.68%	3.27%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	24.76	15.11	11.54	10.23	6.22	9.49	4.22	8.07	8.09	6.57
Enterprise Value to EBITDA (EV/EBITDA)	0.00	204.86	83.42	0.00	18.54	0.00	1,457.68	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	299.43	0.00	19.12	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	272.93	0.00	22.50	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	332.51	0.00	34.06	10.17	20.20	192.86	111.13	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	280.60	41.56	69.68	92.71	0.00	0.00	31.88	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.94	5.03	1.62	0.54	0.46	1.22	1.61	2.38	3.74	2.39
Long-Term Debt to Equity	1.94	5.03	1.62	0.53	0.46	0.81	1.61	2.38	3.62	2.39
Financial Leverage	-1.85	-1.93	-1.28	-1.21	-1.10	-1.12	-1.23	-1.12	-1.58	-1.82
Leverage Ratio	4.15	6.19	4.81	2.57	2.05	2.32	3.30	3.83	5.76	6.15
Compound Leverage Factor	4.82	17.66	-4.07	3.18	1.91	1.81	2.41	3.69	5.66	5.95
Debt to Total Capital	65.98%	83.41%	61.88%	35.09%	31.37%	55.01%	61.65%	70.39%	78.89%	70.52%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.75%	0.00%	18.69%	0.00%	0.00%	2.42%	0.00%
Long-Term Debt to Total Capital	65.98%	83.41%	61.88%	34.34%	31.37%	36.32%	61.65%	70.39%	76.47%	70.52%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	8.79%	7.60%	8.70%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	34.02%	16.59%	29.33%	57.30%	59.93%	44.99%	38.35%	29.61%	21.11%	29.48%
Debt to EBITDA	-13.99	18.20	8.34	-43.17	2.04	-6.48	528.36	-5.84	-4.25	-2.91
Net Debt to EBITDA	14.89	-5.99	-6.05	97.02	-4.59	7.01	-372.40	2.68	2.61	1.84
Long-Term Debt to EBITDA	-13.99	18.20	8.34	-42.25	2.04	-4.28	528.36	-5.84	-4.12	-2.91
Debt to NOPAT	-7.34	-35.47	27.28	-14.94	2.48	-7.55	-58.71	-4.74	-5.83	-4.23
Net Debt to NOPAT	7.82	11.67	-19.78	33.57	-5.57	8.16	41.38	2.18	3.58	2.68
Long-Term Debt to NOPAT	-7.34	-35.47	27.28	-14.62	2.48	-4.98	-58.71	-4.74	-5.66	-4.23
Altman Z-Score	5.26	3.68	3.90	3.52	4.61	3.05	2.01	1.63	1.60	0.96
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	18.13%	14.39%	12.28%	8.79%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.62	5.96	4.80	7.88	9.97	3.56	9.75	7.07	5.90	8.47
Quick Ratio	5.48	5.78	4.20	7.44	9.16	3.16	8.79	6.38	5.20	7.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-163	21	148	100	75	-159	-337	200	-530
Operating Cash Flow to CapEx	179.82%	-972.46%	460.02%	3,415.51%	1,118.35%	102.20%	257.62%	0.00%	-1,293.00%	-1,106.33%
Free Cash Flow to Firm to Interest Expense	-0.45	-3.81	0.47	3.30	1.27	7.85	-16.97	-41.55	2.45	-5.86
Operating Cash Flow to Interest Expense	0.58	-2.62	3.89	13.46	4.40	3.77	3.29	-33.78	-3.78	-5.54
Operating Cash Flow Less CapEx to Interest Expense	0.26	-2.89	3.05	13.07	4.00	0.08	2.02	-4.43	-4.07	-6.04
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.40	0.46	0.30	0.38	0.26	0.32	0.23	0.29	0.24
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.20	0.33	0.60	0.46	0.60	0.62	1.12
Fixed Asset Turnover	3.17	4.07	4.79	4.72	7.86	4.36	4.51	4.65	10.84	8.53
Accounts Payable Turnover	0.00	0.00	0.00	0.07	0.20	0.72	0.75	0.95	0.42	0.33
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	1,861.50	1,114.07	613.25	787.28	605.56	588.96	324.69
Days Payable Outstanding (DPO)	0.00	0.00	0.00	5,369.31	1,861.92	508.16	489.88	385.60	878.19	1,122.68
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	-3,507.81	-747.86	105.08	297.40	219.97	-289.23	-797.99
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-214	-65	-65	-255	-45	-240	-103	-52	-500	-302
Invested Capital Turnover	-1.45	-2.67	-7.93	-3.75	-7.48	-5.11	-4.73	-7.58	-2.85	-1.76
Increase / (Decrease) in Invested Capital	-36	149	0.59	-191	210	-195	138	50	-447	198
Enterprise Value (EV)	7,024	5,632	5,932	6,134	6,981	6,922	3,423	4,740	6,372	4,630
Market Capitalization	7,439	5,797	6,277	7,437	8,497	7,906	4,297	5,365	7,258	5,520
Book Value per Share	$1.67	$0.82	$2.25	$7.62	$10.46	$5.32	$5.47	$4.03	$2.70	$3.73
Tangible Book Value per Share	$1.51	$0.65	$2.08	$7.44	$10.28	$5.12	$5.47	$4.03	$2.70	$3.73
Total Capital	590	600	958	1,829	2,455	1,652	2,012	1,935	1,831	1,996
Total Debt	389	501	593	642	770	909	1,241	1,362	1,445	1,407
Total Long-Term Debt	389	501	593	628	770	600	1,241	1,362	1,400	1,407
Net Debt	-415	-165	-430	-1,442	-1,730	-983	-874	-625	-886	-890
Capital Expenditures (CapEx)	12	12	38	18	31	35	12	-238	24	45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-116	-1.08	-98	-143	-52	-52	-10	-96	-93	13
Debt-free Net Working Capital (DFNWC)	688	664	925	1,941	2,448	1,841	2,104	1,891	2,238	2,311
Net Working Capital (NWC)	688	664	925	1,928	2,448	1,532	2,104	1,891	2,194	2,311
Net Nonoperating Expense (NNE)	35	46	33	-258	23	359	7.47	-17	119	121
Net Nonoperating Obligations (NNO)	-415	-165	-430	-1,442	-1,730	-983	-874	-625	-886	-890
Total Depreciation and Amortization (D&A)	48	48	51	47	11	32	42	35	-0.06	-9.05
Debt-free, Cash-free Net Working Capital to Revenue	-40.83%	-0.29%	-18.98%	-23.80%	-4.63%	-7.10%	-1.29%	-16.30%	-11.82%	1.89%
Debt-free Net Working Capital to Revenue	242.55%	178.16%	179.92%	323.73%	218.03%	252.39%	259.67%	321.97%	284.15%	327.73%
Net Working Capital to Revenue	242.55%	178.16%	179.92%	321.44%	218.03%	210.05%	259.67%	321.97%	278.52%	327.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.74)	($0.72)	$0.08	$2.09	$2.12	($3.23)	($0.20)	($1.90)	($2.56)	($3.04)
Adjusted Weighted Average Basic Shares Outstanding	120.66M	123.75M	124.02M	132.32M	140.00M	139.61M	141.02M	141.85M	143.19M	149.51M
Adjusted Diluted Earnings per Share	($0.74)	($0.72)	$0.08	$2.07	$2.08	($3.23)	($0.20)	($1.90)	($2.56)	($3.04)
Adjusted Weighted Average Diluted Shares Outstanding	120.66M	123.75M	126.10M	134.06M	142.87M	139.61M	141.02M	141.85M	143.19M	149.51M
Adjusted Basic & Diluted Earnings per Share	($0.74)	($0.72)	$0.08	$0.00	$2.12	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	119.72M	120.93M	125.40M	138.40M	139.22M	140.86M	141.69M	142.95M	145.75M	158.96M
Normalized Net Operating Profit after Tax (NOPAT)	-53	-14	22	-43	310	-120	-21	-287	-248	-333
Normalized NOPAT Margin	-18.69%	-3.79%	4.23%	-7.16%	27.64%	-16.52%	-2.61%	-48.88%	-31.44%	-47.16%
Pre Tax Income Margin	-30.99%	-15.42%	-3.26%	-12.70%	30.18%	-18.45%	-3.60%	-43.92%	-42.40%	-65.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.06	-0.47	0.44	-1.37	4.64	-18.10	-4.27	-32.98	-4.17	-5.25
NOPAT to Interest Expense	-1.44	-0.33	0.49	-0.96	3.95	-12.67	-2.26	-35.35	-3.04	-3.68
EBIT Less CapEx to Interest Expense	-2.38	-0.74	-0.40	-1.77	4.25	-21.79	-5.55	-3.63	-4.46	-5.75
NOPAT Less CapEx to Interest Expense	-1.76	-0.60	-0.36	-1.35	3.55	-16.36	-3.54	-6.00	-3.33	-4.18
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-113.54%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-1.35%	-18.89%	0.00%	11.97%	-132.41%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Ionis Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	20.04%	-65.48%	-8.03%	40.82%	-9.74%	113.64%	-8.45%	19.55%	-7.21%	-30.18%
EBITDA Growth	38.04%	-122.37%	-138.50%	9.59%	-202.27%	86.24%	-35.14%	14.08%	-6.39%	-1,510.86%
EBIT Growth	36.93%	-126.48%	-98.75%	19.22%	-158.66%	89.90%	-31.00%	17.13%	-5.47%	-1,800.15%
NOPAT Growth	31.10%	-166.09%	-98.50%	-5.47%	-142.19%	97.06%	-30.98%	26.72%	-3.76%	-1,710.21%
Net Income Growth	43.02%	-123.34%	-90.78%	18.88%	-213.69%	82.33%	-14.86%	22.31%	4.70%	-1,026.51%
EPS Growth	43.10%	-123.27%	-89.13%	18.92%	-212.12%	83.78%	-12.64%	25.00%	7.77%	-1,000.00%
Operating Cash Flow Growth	56.04%	-198.29%	-323.36%	-438.04%	-346.28%	116.42%	-11.90%	-23.13%	-5.47%	-453.38%
Free Cash Flow Firm Growth	-127.84%	-336.64%	304.84%	399.85%	577.56%	326.18%	-133.83%	-147.09%	-180.81%	-162.13%
Invested Capital Growth	6.68%	49.03%	-319.84%	-178.05%	-217.11%	-855.25%	-0.24%	14.43%	19.49%	39.57%
Revenue Q/Q Growth	19.42%	-4.93%	-14.07%	44.35%	-23.46%	125.03%	-63.18%	88.50%	-40.59%	69.32%
EBITDA Q/Q Growth	46.64%	-10.29%	-116.76%	29.13%	-78.40%	94.98%	-2,029.23%	54.94%	-120.92%	24.00%
EBIT Q/Q Growth	44.34%	-7.07%	-95.43%	30.64%	-78.22%	95.82%	-2,435.01%	56.12%	-126.80%	24.68%
NOPAT Q/Q Growth	30.83%	-251.66%	45.13%	20.98%	-58.84%	95.73%	-2,342.22%	55.80%	-124.93%	25.45%
Net Income Q/Q Growth	55.30%	-11.57%	-137.12%	31.40%	-72.83%	93.72%	-1,441.65%	53.60%	-112.00%	25.72%
EPS Q/Q Growth	55.41%	-12.12%	-135.14%	31.03%	-71.67%	94.17%	-1,533.33%	54.08%	-111.11%	30.53%
Operating Cash Flow Q/Q Growth	-35.00%	-719.50%	33.07%	27.34%	-11.97%	130.15%	-556.22%	20.05%	4.08%	-1.00%
Free Cash Flow Firm Q/Q Growth	35.40%	-269.29%	256.07%	-19.46%	2.88%	74.90%	-121.33%	-12.10%	-76.55%	-34.48%
Invested Capital Q/Q Growth	6.26%	67.88%	-867.70%	4.56%	-6.90%	3.25%	6.30%	18.52%	-0.57%	27.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	99.05%	97.57%	98.97%	98.65%	98.48%	99.06%	98.20%	98.15%	99.20%	98.31%
EBITDA Margin	-29.29%	-33.98%	-85.71%	-42.08%	-98.08%	-2.19%	-126.51%	-30.24%	-112.46%	-50.48%
Operating Margin	-37.03%	-136.95%	-87.45%	-47.87%	-99.35%	-1.89%	-125.12%	-29.34%	-111.09%	-48.91%
EBIT Margin	-34.08%	-38.38%	-87.28%	-41.94%	-97.65%	-1.81%	-124.89%	-29.07%	-110.99%	-49.37%
Profit (Net Income) Margin	-29.41%	-34.52%	-95.25%	-45.27%	-102.22%	-2.85%	-119.50%	-29.42%	-104.98%	-46.05%
Tax Burden Percent	100.61%	118.27%	110.08%	110.13%	104.69%	334.89%	100.05%	100.10%	97.49%	97.49%
Interest Burden Percent	85.80%	76.05%	99.14%	98.02%	99.99%	46.98%	95.64%	101.10%	97.03%	95.69%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	1.30%	-40.12%	-54.99%	-58.69%	-90.01%	-76.34%	-98.27%	-105.71%	-73.38%	-93.10%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-12.34%	-8.76%	-18.60%	-9.75%	-22.43%	-0.52%	-34.34%	-8.35%	-29.64%	-11.62%
Return on Assets (ROA)	-10.65%	-7.88%	-20.30%	-10.52%	-23.48%	-0.81%	-32.86%	-8.45%	-28.03%	-10.84%
Return on Common Equity (ROCE)	1.30%	-40.12%	-54.99%	-58.69%	-90.01%	-76.34%	-98.27%	-105.71%	-73.38%	-93.10%
Return on Equity Simple (ROE_SIMPLE)	1.23%	0.00%	-67.59%	-72.15%	-129.80%	0.00%	-129.76%	-138.70%	-54.16%	0.00%
Net Operating Profit after Tax (NOPAT)	-41	-146	-80	-63	-100	-4.29	-105	-46	-104	-78
NOPAT Margin	-25.92%	-95.87%	-61.22%	-33.51%	-69.54%	-1.32%	-87.58%	-20.54%	-77.76%	-34.24%
Net Nonoperating Expense Percent (NNEP)	-0.76%	12.43%	-4.87%	-2.59%	-5.93%	-0.66%	-4.25%	-2.52%	-3.81%	-3.01%
Return On Investment Capital (ROIC_SIMPLE)	-	-7.53%	-	-	-	-0.23%	-	-	-	-3.89%
Cost of Revenue to Revenue	0.95%	2.43%	1.03%	1.35%	1.52%	0.94%	1.80%	1.85%	0.80%	1.69%
SG&A Expenses to Revenue	21.54%	31.57%	34.87%	24.49%	48.51%	21.88%	44.05%	28.91%	46.06%	38.87%
R&D to Revenue	114.54%	202.96%	151.55%	122.03%	149.32%	79.06%	179.26%	98.59%	164.23%	108.35%
Operating Expenses to Revenue	136.08%	234.53%	186.42%	146.52%	197.83%	100.94%	223.32%	127.49%	210.29%	147.22%
Earnings before Interest and Taxes (EBIT)	-54	-58	-114	-79	-141	-5.89	-149	-65	-149	-112
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-47	-52	-112	-79	-141	-7.10	-151	-68	-150	-114
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	10.56	9.37	10.50	13.71	20.61	18.77	20.98	26.38	8.84	9.38
Price to Tangible Book Value (P/TBV)	11.12	9.37	10.50	13.71	20.61	18.77	20.98	26.38	8.84	9.38
Price to Revenue (P/Rev)	7.17	9.13	8.87	9.31	10.57	9.22	8.01	8.55	7.29	7.83
Price to Earnings (P/E)	857.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	6.31	8.07	7.15	7.86	9.22	8.09	6.97	7.72	5.95	6.57
Enterprise Value to EBITDA (EV/EBITDA)	111.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	523.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	460.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	42.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	16,598.04	0.00	69.84	0.00	0.00	31.88	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.06	2.38	2.78	3.44	4.45	3.74	4.73	5.31	2.12	2.39
Long-Term Debt to Equity	2.06	2.38	2.78	3.44	4.45	3.62	4.58	5.15	2.05	2.39
Financial Leverage	-1.30	-1.12	-1.52	-1.62	-1.75	-1.58	-2.29	-2.30	-1.95	-1.82
Leverage Ratio	4.30	3.83	4.52	5.15	5.89	5.76	7.21	8.18	6.15	6.15
Compound Leverage Factor	3.69	2.91	4.48	5.05	5.89	2.70	6.90	8.27	5.97	5.88
Debt to Total Capital	67.32%	70.39%	73.56%	77.48%	81.65%	78.89%	82.54%	84.16%	67.96%	70.52%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	2.42%	2.61%	2.67%	2.15%	0.00%
Long-Term Debt to Total Capital	67.32%	70.39%	73.56%	77.48%	81.65%	76.47%	79.93%	81.50%	65.81%	70.52%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	32.68%	29.61%	26.44%	22.52%	18.35%	21.11%	17.46%	15.84%	32.04%	29.48%
Debt to EBITDA	24.81	-5.84	-4.54	-5.09	-3.65	-4.25	-3.70	-3.81	-3.73	-2.91
Net Debt to EBITDA	-15.34	2.68	3.33	3.15	2.17	2.61	2.12	1.84	2.86	1.84
Long-Term Debt to EBITDA	24.81	-5.84	-4.54	-5.09	-3.65	-4.12	-3.58	-3.69	-3.61	-2.91
Debt to NOPAT	102.15	-4.74	-4.14	-4.47	-3.61	-5.83	-5.15	-5.49	-5.42	-4.23
Net Debt to NOPAT	-63.18	2.18	3.04	2.76	2.14	3.58	2.95	2.65	4.16	2.68
Long-Term Debt to NOPAT	102.15	-4.74	-4.14	-4.47	-3.61	-5.66	-4.99	-5.31	-5.25	-4.23
Altman Z-Score	2.48	1.90	1.54	1.68	1.58	1.97	1.54	1.80	1.52	1.36
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.59	7.07	9.81	9.09	6.39	5.90	7.37	7.61	8.91	8.47
Quick Ratio	6.99	6.38	9.05	8.28	5.53	5.20	6.73	6.79	8.15	7.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-53	-196	306	246	253	443	-103	-116	-205	-275
Operating Cash Flow to CapEx	-440.80%	-4,836.80%	-1,279.53%	-810.62%	-5,092.11%	0.00%	-3,337.15%	-1,923.00%	-1,269.77%	-455.50%
Free Cash Flow to Firm to Interest Expense	-24.81	-113.20	17.86	12.35	11.53	19.78	-4.68	-5.09	-9.02	-12.05
Operating Cash Flow to Interest Expense	-11.42	-115.65	-7.83	-4.88	-4.96	1.47	-6.78	-5.26	-5.07	-5.08
Operating Cash Flow Less CapEx to Interest Expense	-14.01	-118.04	-8.44	-5.48	-5.06	1.50	-6.98	-5.53	-5.47	-6.20
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.23	0.21	0.23	0.23	0.29	0.28	0.29	0.27	0.24
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.58	0.60	0.49	0.40	0.42	0.62	0.38	0.43	0.39	1.12
Fixed Asset Turnover	4.85	4.65	4.38	4.69	4.89	10.84	9.83	9.71	10.47	8.53
Accounts Payable Turnover	0.88	0.95	0.85	0.53	0.75	0.42	0.84	0.70	1.42	0.33
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	628.30	605.56	747.39	911.37	865.63	588.96	963.06	856.04	944.74	324.69
Days Payable Outstanding (DPO)	416.74	385.60	430.41	690.77	489.31	878.19	432.91	524.78	256.20	1,122.68
Cash Conversion Cycle (CCC)	211.57	219.97	316.99	220.60	376.32	-289.23	530.15	331.25	688.55	-797.99
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-163	-52	-506	-483	-517	-500	-508	-414	-416	-302
Invested Capital Turnover	-5.19	-7.58	-1.84	-1.92	-1.81	-2.85	-1.53	-1.81	-1.72	-1.76
Increase / (Decrease) in Invested Capital	12	50	-386	-309	-354	-447	-1.20	70	101	198
Enterprise Value (EV)	5,521	4,740	4,116	4,960	5,669	6,372	5,415	6,279	4,779	4,630
Market Capitalization	6,278	5,365	5,109	5,871	6,501	7,258	6,220	6,957	5,857	5,520
Book Value per Share	$4.19	$4.03	$3.40	$2.99	$2.20	$2.70	$2.04	$1.81	$4.53	$3.73
Tangible Book Value per Share	$3.98	$4.03	$3.40	$2.99	$2.20	$2.70	$2.04	$1.81	$4.53	$3.73
Total Capital	1,819	1,935	1,840	1,902	1,719	1,831	1,699	1,665	2,067	1,996
Total Debt	1,224	1,362	1,354	1,474	1,404	1,445	1,402	1,401	1,405	1,407
Total Long-Term Debt	1,224	1,362	1,354	1,474	1,404	1,400	1,358	1,357	1,360	1,407
Net Debt	-757	-625	-993	-912	-832	-886	-804	-677	-1,078	-890
Capital Expenditures (CapEx)	5.54	4.14	10	12	2.14	-0.82	4.49	6.23	9.06	25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-113	-96	-63	-57	-55	-93	-74	-11	-30	13
Debt-free Net Working Capital (DFNWC)	1,869	1,891	2,283	2,329	2,180	2,238	2,132	2,068	2,454	2,311
Net Working Capital (NWC)	1,869	1,891	2,283	2,329	2,180	2,194	2,088	2,023	2,409	2,311
Net Nonoperating Expense (NNE)	5.58	-93	44	22	47	4.98	38	20	36	27
Net Nonoperating Obligations (NNO)	-757	-625	-993	-912	-832	-886	-804	-677	-1,078	-890
Total Depreciation and Amortization (D&A)	7.65	6.68	2.05	-0.27	-0.62	-1.21	-1.94	-2.64	-1.97	-2.51
Debt-free, Cash-free Net Working Capital to Revenue	-12.91%	-16.30%	-11.00%	-8.98%	-8.97%	-11.82%	-9.50%	-1.36%	-3.68%	1.89%
Debt-free Net Working Capital to Revenue	213.44%	321.97%	396.44%	369.30%	354.52%	284.15%	274.58%	254.18%	305.55%	327.73%
Net Working Capital to Revenue	213.44%	321.97%	396.44%	369.30%	354.52%	278.52%	268.86%	248.72%	300.01%	327.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.33)	($0.37)	($0.87)	($0.60)	($1.03)	($0.06)	($0.98)	($0.45)	($0.95)	($0.66)
Adjusted Weighted Average Basic Shares Outstanding	141.95M	141.85M	142.74M	143.10M	143.32M	143.19M	145.54M	145.96M	148.59M	149.51M
Adjusted Diluted Earnings per Share	($0.33)	($0.37)	($0.87)	($0.60)	($1.03)	($0.06)	($0.98)	($0.45)	($0.95)	($0.66)
Adjusted Weighted Average Diluted Shares Outstanding	141.95M	141.85M	142.74M	143.10M	143.32M	143.19M	145.54M	145.96M	148.59M	149.51M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	142.05M	142.95M	143.09M	143.33M	143.47M	145.75M	145.97M	146.21M	157.90M	158.96M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-146	-80	-63	-100	-4.29	-105	-46	-104	-78
Normalized NOPAT Margin	-25.92%	-95.87%	-61.22%	-33.51%	-69.54%	-1.32%	-87.58%	-20.54%	-77.76%	-34.24%
Pre Tax Income Margin	-29.24%	-29.19%	-86.53%	-41.11%	-97.64%	-0.85%	-119.44%	-29.39%	-107.69%	-47.24%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-25.45	-33.68	-6.65	-3.96	-6.41	-0.26	-6.75	-2.87	-6.54	-4.89
NOPAT to Interest Expense	-19.36	-84.12	-4.67	-3.17	-4.56	-0.19	-4.73	-2.03	-4.59	-3.39
EBIT Less CapEx to Interest Expense	-28.04	-36.07	-7.26	-4.56	-6.50	-0.23	-6.95	-3.15	-6.94	-6.01
NOPAT Less CapEx to Interest Expense	-21.95	-86.51	-5.28	-3.77	-4.66	-0.15	-4.94	-2.30	-4.98	-4.51
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Ionis Pharmaceuticals' Financials

When does Ionis Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Ionis Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Ionis Pharmaceuticals' net income changed over the last 9 years?

Ionis Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$453.90 million in 2024, rising from -$88.28 million in 2015. The previous period was -$366.29 million in 2023.

What is Ionis Pharmaceuticals's operating income?

Ionis Pharmaceuticals's total operating income in 2024 was -$475.08 million, based on the following breakdown:

Total Gross Profit: $693.92 million
Total Operating Expenses: $1.17 billion

How has Ionis Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Ionis Pharmaceuticals' total revenue changed from $283.70 million in 2015 to $705.14 million in 2024, a change of 148.5%.

How much debt does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals' total liabilities were at $2.42 billion at the end of 2024, a 7.2% decrease from 2023, and a 223.3% increase since 2015.

How much cash does Ionis Pharmaceuticals have?

In the past 9 years, Ionis Pharmaceuticals' cash and equivalents has ranged from $84.69 million in 2016 to $869.19 million in 2021, and is currently $242.08 million as of their latest financial filing in 2024.

How has Ionis Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Ionis Pharmaceuticals' book value per share changed from 1.67 in 2015 to 3.73 in 2024, a change of 122.9%.

Related Companies

This page (NASDAQ:IONS) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Financials

Frequently Asked Questions About Ionis Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Financials

Annual Income Statements for Ionis Pharmaceuticals

Quarterly Income Statements for Ionis Pharmaceuticals

Annual Cash Flow Statements for Ionis Pharmaceuticals

Quarterly Cash Flow Statements for Ionis Pharmaceuticals

Annual Balance Sheets for Ionis Pharmaceuticals

Quarterly Balance Sheets for Ionis Pharmaceuticals

Annual Metrics and Ratios for Ionis Pharmaceuticals

Quarterly Metrics and Ratios for Ionis Pharmaceuticals

Frequently Asked Questions About Ionis Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools